The board overhaul and share conversion signal the completion of the Azora Therapeutics acquisition integration. Monitor for Nasdaq listing approval (pending per prior DEFA14A) and any subsequent equity financings given the small market cap.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 9 $3.75entry
- T+1 · 7d ago +0.27%α +0.63% · $3.76
- T+5 · yesterday +1.60%α +3.29% · $3.81
- T+6 · todayOpen
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Azora Therapeutics appointed three new independent directors (Aida Habtezion, Paul Hastings, Thomas Soloway) and four prior directors resigned, reducing the board to five members. Separately, 9,924,260 shares of common stock were issued upon automatic conversion of Series A Preferred Stock, increasing the share count to 14,243,129. The board changes follow a contested annual meeting and the conversion resolves the shareholder approval condition for Nasdaq listing rules.
Key Facts
- Three new independent directors appointed on November 3, 2026: Aida Habtezion (Pfizer CMO), Paul Hastings (Nkarta CEO), Thomas Soloway (T-knife CEO).
- Four directors resigned: J. Kermit Anderson, Cary J. Claiborne, Robertson H. Gilliland, Kevin Schuyler; resignations not due to disagreements.
- Board reduced to five members; Matthew Davidson appointed chair.
- 9,924.260 shares of Series A Preferred Stock automatically converted into 9,924,260 shares of common stock on November 2, 2026.
- Post-conversion shares outstanding: 14,243,129 as of November 4, 2026.
- 3,006.341 shares of Series A Preferred Stock remain outstanding subject to beneficial ownership limitations.
- Conversion follows stockholder approval at reconvened 2026 Annual Meeting on October 28, 2026, for Nasdaq Listing Rules 5635(a) and 5635(b).
Financial Impact
9,924,260 new common shares issued via Series A conversion; post-conversion share count 14,243,129. At $10M market cap, the new shares represent approximately 70% of the pre-conversion float, causing massive dilution.
Risk Factors
- Nasdaq conditional listing approval remains pending, creating delisting risk.
- Remaining 3,006.341 Series A Preferred shares can still convert, adding further dilution.
- Compensation arrangements for new directors not yet finalized, may involve additional equity grants.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-117201 |
| Document: 0001213900-26-117201-index-headers.html | 0001213900-26-117201 |
| Document: 0001213900-26-117201-index.html | 0001213900-26-117201 |
| Document: 0001213900-26-117201.txt | 0001213900-26-117201 |
Track record
5 reports on AZR
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today S-3 Bearish 6/10 Entry $3.81 Now $3.66 +3.81% settles Nov 24
- Nov 12, 20265d ago 8-K Neutral 4/10 Entry $4.09 Now $3.66 −10.39% settles Nov 20
- Nov 10, 20267d ago 3 Neutral 2/10 Entry $3.76 to $3.67 Now $3.66 −2.53% ▼ −2.53% −0.20% vs SPY
- Nov 9, 20268d ago 8-K Neutral 4/10 Viewing Entry $3.75 to $3.81 Now $3.66 −2.27% ▲ +1.60% +3.29% vs SPY
- Nov 3, 202614d ago SC 13G/A Bearish 4/10 Entry $4.15 to $3.76 Now $3.66 +11.69% ▲ +9.40% +8.81% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers